ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1118

US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation

Ting-Chun Yeh1, Yolaine Jeune-Smith 1, Eli Phillips 1, Ajeet Gajra 1 and Bruce Feinberg 1, 1Cardinal Health Specialty Solutions, Dublin, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Access to care, Anti-TNF therapy and rheumatoid arthritis (RA), biosimilars, prescribing trends

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Health Services Research Poster II – ACR/ARP

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for biosimilars.1 Based upon scientific justification including: PK, PD, efficacy, safety, and immunogenicity data, two tumor necrosis factor inhibitor (TNFi) biosimilars were approved for all reference biologic indications (e.g., ankylosing spondylitis, psoriatic arthritis) despite clinical efficacy studies in just one indication (rheumatoid arthritis)a—a process known as extrapolation. Non-inferiority trial design for one approved indication and extrapolation based labeling for other indications represent potential barriers to physician adoption of biosimilars. This study aimed to assess community rheumatologists’ perceptions and utilization patterns of the two TNFi biosimilars approved and commercialized in the US.

Methods: A live meeting in November 2018 surveyed US-based community rheumatologists regarding their perceptions and utilization patterns of biosimilars.  Participants completed a web-based premeeting survey and live queries captured via an audience response system. Physician characteristics and responses were summarized using descriptive statistics.

Results: 54 rheumatologists participated describing their practices as: urban 48%, suburban 45%, and rural 7%. Median years in practice were 19 years (range 3-40). 67% have prescribed biosimilars since being commercially available in late 2016. Regarding their familiarity with biosimilars and the FDA approval process: 34% very familiar, 56% somewhat familiar, and 10% not.  A minority of the rheumatologists (15%) expressed comfort with current biosimilar safety/efficacy data and FDA regulation.  Regarding extrapolation-based labeling: 53% said they would not prescribe without data for a specific indication (Figure 1).   Regarding additional data: 58% indicated that real-world evidence would suffice for an extrapolated indication, while 23% would only accept randomized controlled trials (Figure 2).  Participants stated they are most likely to prescribe a biosimilar when it provides cost-savings to the patient or their practice with 48% requiring a 31-50% discount from the reference product for them to consider a biosimilar over the reference biologic. Various concerns remain regarding prescribing a biosimilar, including FDA evaluation process and payer coverage and/or reimbursement for a biosimilar.

Conclusion: The majority of the participating rheumatologists appear to be familiar with biosimilars and its FDA approval process, and they are open to prescribing them, especially when there are cost-savings. Further safety/efficacy data is needed for rheumatologists to willingly expand their use of biosimilars to the indications that were approved based on extrapolation.
1FDA.gov
aOne of the TNFi biosimilars had an additional clinical study in Crohn’s disease.


Disclosure: T. Yeh, Cardinal Health, 3; Y. Jeune-Smith, Cardinal Health, 3; E. Phillips, Cardinal Health, 3; A. Gajra, Cardinal Health, 3, ICON plc, 3; B. Feinberg, Cardinal Health, 3, 4.

To cite this abstract in AMA style:

Yeh T, Jeune-Smith Y, Phillips E, Gajra A, Feinberg B. US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/us-community-rheumatologists-knowledge-and-perceptions-of-biosimilar-expanded-indication-approval-by-extrapolation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/us-community-rheumatologists-knowledge-and-perceptions-of-biosimilar-expanded-indication-approval-by-extrapolation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology